Linsitinib (OSI-906)

目录号:S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献33篇:

客户使用该产品的6个实验数据:

  • (e) c-peptide from these mice 240 min after respective treatments.

    Nature, 2018, 560(7719):499-503. Linsitinib (OSI-906) purchased from Selleck.

    Inhibition of IGF receptor by the IGFR inhibitor linsitinib reduced ERK1/2 signaling activation particularly in U87MG RG7388 resistant cells.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1580. Linsitinib (OSI-906) purchased from Selleck.

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活,IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体,具有良好的代谢稳定性。OSI-906浓度为1μM时,完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖,包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系,EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NGfsUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPkdGtwUUN3ME2wMlAzQDB4IN88US=> MoTEV2FPT0WU
KS-1 M4CybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTM[4c2UUN3ME2wMlA{QDN3IN88US=> MlHlV2FPT0WU
TE-11 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEe4NlIh|ryP NFT1VFJUSU6JRWK=
EW-1 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEi1PFUh|ryP MV;TRW5ITVJ?
HMV-II MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHUTFdKSzVyPUCuNFg5PDZizszN MoTuV2FPT0WU
COLO-205 MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rLXGlEPTB;MD6xNFQ2PCEQvF2= MnzCV2FPT0WU
ES1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH74NpFKSzVyPUCuNVA3QTZizszN MVzTRW5ITVJ?
GDM-1 NV[yXpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMUO2O|Ih|ryP NXfwSnBWW0GQR1XS
ML-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;VTWM2OD1yLkG1PFk3KM7:TR?= NYrxZXhOW0GQR1XS
Saos-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK0TWM2OD1yLkG2OVI3KM7:TR?= MojzV2FPT0WU
NCI-H1355 MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TwUmlEPTB;MD6xPFE{PSEQvF2= NUjhWJdnW0GQR1XS
G-401 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvLcZJKSzVyPUCuNVgzOyEQvF2= NWfrdHJIW0GQR1XS
EW-16 M2GyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3ySJhpUUN3ME2wMlE5Pzd5IN88US=> NF\MRpZUSU6JRWK=
EW-7 NGLxSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOzVodKSzVyPUCuNVg5QDFizszN MXnTRW5ITVJ?
NCI-H727 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD2TpdKSzVyPUCuNVk4QTRizszN NVTMWYx4W0GQR1XS
LCLC-97TM1 NXnVZlBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Pd5JKSzVyPUCuNlA6PTVizszN NVvqbndmW0GQR1XS
NCI-H650 NFLXVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnqXZFKSzVyPUCuNlE{QDRizszN NGX3dpJUSU6JRWK=
NCI-H2122 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPzZmgxUUN3ME2wMlI{Ojl7IN88US=> NVy2c|l3W0GQR1XS
SK-N-DZ NEPyc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\jTWM2OD1yLkKzOlk5KM7:TR?= NGHTeodUSU6JRWK=
HT-29 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzRTHJKSzVyPUCuNlQzPDhizszN MVPTRW5ITVJ?
LB771-HNC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP6NYJKSzVyPUCuNlU6OTVizszN Mn\tV2FPT0WU
HT-144 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj6TWM2OD1yLkK2NVkyKM7:TR?= MnTJV2FPT0WU
LAN-6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMk[zOFgh|ryP NI\2dG9USU6JRWK=
EW-18 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMkewNFEh|ryP NVWxWIdwW0GQR1XS
LS-1034 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMkexN|Ih|ryP MmPKV2FPT0WU
EW-11 NUTGXXpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvkb3RFUUN3ME2wMlI5PDN{IN88US=> MV;TRW5ITVJ?
SNU-C1 NIjUOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvLWG9[UUN3ME2wMlI6OzF|IN88US=> MmDUV2FPT0WU
RS4-11 NGPsO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TYbmlEPTB;MD6zN|c2QCEQvF2= NXv0XJZVW0GQR1XS
ES4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDCTWM2OD1yLkSxNFM5KM7:TR?= MnjmV2FPT0WU
COLO-320-HSR NX6yPGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnMWXBtUUN3ME2wMlQyOzZ6IN88US=> M3:wfnNCVkeHUh?=
NB10 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X3bWlEPTB;MD60OVQ{PyEQvF2= NFTvTohUSU6JRWK=
BFTC-905 NGPU[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLrTmd4UUN3ME2wMlQ3PzV6IN88US=> NEPyU29USU6JRWK=
A375 M2\kN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjSZmFMUUN3ME2wMlQ4PjF5IN88US=> M2LEOHNCVkeHUh?=
SJRH30 NFK3ZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT3RoFKSzVyPUCuOVA5OjJizszN NVrCO2xGW0GQR1XS
NOS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNUKyOlch|ryP MWrTRW5ITVJ?
SIG-M5 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXVUVBIUUN3ME2wMlU{PTV5IN88US=> M2DMXXNCVkeHUh?=
DOK MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwNUW2JO69VQ>? MXfTRW5ITVJ?
NB69 NUnuSHY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXFXZhKSzVyPUCuOVgzPTdizszN NXn5bZlDW0GQR1XS
SK-NEP-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwNkCyN|Yh|ryP Mn;HV2FPT0WU
SK-MM-2 NIrDZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT3R|ZKSzVyPUCuOlU1QTFizszN NEnsV4RUSU6JRWK=
NCI-H358 NIjqOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7EZZJKSzVyPUCuOlcxQDJizszN M1TPXXNCVkeHUh?=
RH-1 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwN{S4OVkh|ryP Mn;rV2FPT0WU
NH-12 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HSWmlEPTB;MD63OlA1PiEQvF2= MVjTRW5ITVJ?
TE-12 M1HsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjVeW16UUN3ME2wMlc3PDh4IN88US=> Mm\FV2FPT0WU
COLO-668 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITyR29KSzVyPUCuPFQ3PjZizszN M1H6TnNCVkeHUh?=
PANC-08-13 NXT1cFRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH0TWM2OD1yLki2N|c4KM7:TR?= MUTTRW5ITVJ?
HCC2998 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDueI1KUUN3ME2wMlg5OjZ|IN88US=> NH7tR2hUSU6JRWK=
ABC-1 NYLUZ21yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknvTWM2OD1yLkmwN|UzKM7:TR?= NGr4V4NUSU6JRWK=
ES6 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwOUGwOlYh|ryP NGO2OWhUSU6JRWK=
SNU-387 MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTqOYFKSzVyPUCuPVk{QTNizszN NVTQdIdGW0GQR1XS
CMK MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jUUmlEPTB;MD65PVkzQSEQvF2= NHjv[nlUSU6JRWK=
SJSA-1 M3jGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwMEO2OVMh|ryP MUXTRW5ITVJ?
SIMA Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHZUo9HUUN3ME2xMlA3QDJ3IN88US=> M3;aZXNCVkeHUh?=
ES3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnCXJhKSzVyPUGuNVIzQTdizszN M17pSHNCVkeHUh?=
IGROV-1 NGe0cXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwMUW0OFQh|ryP MoP5V2FPT0WU
MEL-JUSO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HOOWlEPTB;MT6xOVc2QSEQvF2= NIrZVIpUSU6JRWK=
T84 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrETWM2OD1zLkKwPVE1KM7:TR?= NU\ROndbW0GQR1XS
CAL-85-1 M3fpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHzTWM2OD1zLkKzNVM5KM7:TR?= NW[0ZWp6W0GQR1XS
RD NH7hO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwMk[0OVUh|ryP MYjTRW5ITVJ?
TE-8 M2nJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFwM{G0OlIh|ryP MlHGV2FPT0WU
L-363 M3HSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjROY02UUN3ME2xMlM1OjB6IN88US=> NFzWWYJUSU6JRWK=
EKVX MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DqWGlEPTB;MT6zOFU3QCEQvF2= Mnu2V2FPT0WU
SK-MEL-3 NV3LVnFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwNEi1OVYh|ryP NVnPcnhKW0GQR1XS
TGBC24TKB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwNUCxPVMh|ryP NXvh[|ZJW0GQR1XS
NCI-H1770 M2nhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzke|UzUUN3ME2xMlUyOTF|IN88US=> M3jYbHNCVkeHUh?=
HuH-7 MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jFRmlEPTB;MT62NFA6QCEQvF2= MXPTRW5ITVJ?
HL-60 NGrNboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjOOmZpUUN3ME2xMlY3QTJ6IN88US=> M3\aWnNCVkeHUh?=
TE-1 MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXtNHhKSzVyPUGuO|A6PDVizszN MnvxV2FPT0WU
LC-2-ad NEX3XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHNTWM2OD1zLkezPFg4KM7:TR?= NITnfoJUSU6JRWK=
LB647-SCLC NGDVXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4POT2lEPTB;MT63OlU5OyEQvF2= NWDW[XpkW0GQR1XS
NCI-H2171 NEK4VGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LpRWlEPTB;MT63O|cyPiEQvF2= MUTTRW5ITVJ?
SK-PN-DW NV7kb4plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7NOGlOUUN3ME2xMlkyOjl6IN88US=> MWXTRW5ITVJ?
MC-IXC NYDzPWUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f2PGlEPTB;MT65PFk5KM7:TR?= NGnLeVdUSU6JRWK=
LS-513 M2HsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJwMEWzNFUh|ryP NX\TWppHW0GQR1XS
EW-3 M3jpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHITWM2OD1{LkC5PFQ1KM7:TR?= M3fvOnNCVkeHUh?=
OPM-2 MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jQUmlEPTB;Mj6xNFIh|ryP NWDqUJpHW0GQR1XS
LP-1 M2TIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwMkW4NFch|ryP MXLTRW5ITVJ?
LU-134-A MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJwMke3JO69VQ>? MUDTRW5ITVJ?
CP66-MEL NEnyTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrXOZc4UUN3ME2yMlI6ODF2IN88US=> NF7je3dUSU6JRWK=
HCC1143 NUfnUolzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjCSmVMUUN3ME2yMlQ2OzZ6IN88US=> M2jRZnNCVkeHUh?=
LOXIMVI MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DWVWlEPTB;Mj62NFIyKM7:TR?= MkH2V2FPT0WU
TE-10 NEPne4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXJTWM2OD1{LkewPFM5KM7:TR?= NUXUT444W0GQR1XS
NCI-H1882 NVzrZ4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13SeGlEPTB;Mj63OVIzPyEQvF2= M2S4VXNCVkeHUh?=
CHP-126 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\5dWNGUUN3ME2yMlc3OzF5IN88US=> MVTTRW5ITVJ?
NCI-H1623 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmryTWM2OD1{LkmyNFI1KM7:TR?= MXfTRW5ITVJ?
GB-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDUTWM2OD1{LkmzOFA1KM7:TR?= NUDkb|JVW0GQR1XS
RCC10RGB MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwOUWyPFEh|ryP M3rES3NCVkeHUh?=
NCI-H2141 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTpW2tMUUN3ME2yMlk3QDl4IN88US=> NFfaR4JUSU6JRWK=
GI-ME-N NVjFfXVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\uZodKSzVyPUOuNFA2PjVizszN NVHlXJZbW0GQR1XS
NCI-H526 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jwZmlEPTB;Mz6wOFA5PSEQvF2= MUDTRW5ITVJ?
NCI-H747 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX1VIk{UUN3ME2zMlA1QTl{IN88US=> MYXTRW5ITVJ?
SNU-423 M13xbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfjTWM2OD1|LkKwN|E{KM7:TR?= NE[zd3VUSU6JRWK=
A427 NEe3NWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwMkW2PVkh|ryP M1fDbHNCVkeHUh?=
CAL-12T NUXqOHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PlPWlEPTB;Mz60NFcyOyEQvF2= NH\JemZUSU6JRWK=
LU-99A NIf2[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnETWM2OD1|LkS3NVA2KM7:TR?= Mn7UV2FPT0WU
MS-1 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPVTWM2OD1|LkWzOFI6KM7:TR?= NFnsRYZUSU6JRWK=
SK-LU-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuyTWM2OD1|Lke2Nlk2KM7:TR?= MXXTRW5ITVJ?
SW837 NVGzdm91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyzTWM2OD1|Lke2N|M{KM7:TR?= M2PwNXNCVkeHUh?=
ES8 NHXQ[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jkV2lEPTB;Mz64N|g4PyEQvF2= MlK0V2FPT0WU
MZ2-MEL M3\zSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPxTWM2OD1|LkmyNFg3KM7:TR?= Ml\FV2FPT0WU
TGW NU\p[25ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r2NmlEPTB;ND6wNVMyOSEQvF2= NYPoPVI6W0GQR1XS
GP5d MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK5NmNKSzVyPUSuNFU{PjJizszN NGfnZo9USU6JRWK=
BB49-HNC NHj5UnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X0b2lEPTB;ND6xOVIyOyEQvF2= M2fIbHNCVkeHUh?=
NB13 M3i2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTRwMk[4PFch|ryP NGLhR3RUSU6JRWK=
NTERA-S-cl-D1 NXHjRYtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\Wd3RyUUN3ME20MlI5PjF3IN88US=> NXvSZ2poW0GQR1XS
NCI-H1648 NES5[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDCVYk2UUN3ME20MlI6QDF7IN88US=> NGXReVdUSU6JRWK=
LCLC-103H MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTRwM{KxPVUh|ryP Ml3nV2FPT0WU
LS-411N NGLSUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH1VmdiUUN3ME20MlQ1QDh3IN88US=> MUHTRW5ITVJ?
NCI-H1092 NH7rco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTRwNEW2PFch|ryP Mm[xV2FPT0WU
PANC-10-05 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\kemlEPTB;ND62PVg1KM7:TR?= NXvDeFRRW0GQR1XS
DK-MG M17qXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13jTGlEPTB;ND64NFk{OyEQvF2= MVfTRW5ITVJ?
OVCAR-5 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXKTWM2OD12LkixNlI3KM7:TR?= M3XqcnNCVkeHUh?=
CAL-39 NF;sdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHPZZJKSzVyPUSuPFc3PyEQvF2= NHjkSpJUSU6JRWK=
TE-441-T MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\wO2lEPTB;ND65NFU{PyEQvF2= MkfyV2FPT0WU
MOLT-16 NVP1OYxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LuUmlEPTB;ND65OVI2OyEQvF2= MlzsV2FPT0WU
MCF7 M3jObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjVXmJKSzVyPUWuNVQ2OTdizszN MYLTRW5ITVJ?
CAPAN-1 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi4bIhKSzVyPUWuNlU4ODdizszN MYrTRW5ITVJ?
PSN1 M1z6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTVwMkeyN|Uh|ryP M3i0TXNCVkeHUh?=
NCI-H292 NUnzNlBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXftO2RwUUN3ME21MlMxODR2IN88US=> NVvjcmN2W0GQR1XS
CPC-N MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;Ccm5PUUN3ME21MlM6PDF7IN88US=> MUDTRW5ITVJ?
DoTc2-4510 NWfvfJFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTVwNEWzO|Eh|ryP NUDKN5dtW0GQR1XS
LB1047-RCC NEi3fnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfqcplMUUN3ME21MlU2QTN|IN88US=> MVPTRW5ITVJ?
MHH-ES-1 M1r6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\QOWlEPTB;NT61PVkxPyEQvF2= NYDPdIVkW0GQR1XS
NMC-G1 M{mxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7lfYNKSzVyPUWuO|AzOjdizszN M3XCNHNCVkeHUh?=
SW1710 NHrL[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L2dWlEPTB;NT63OFc2OSEQvF2= MVvTRW5ITVJ?
YAPC NVL3bZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTVwN{[yNFEh|ryP NFuxXWxUSU6JRWK=
22RV1 NYDJZXZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jMVWlEPTB;NT64NFAyQSEQvF2= NF7WeW9USU6JRWK=
COLO-679 NELy[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXIdIZKSzVyPUWuPFg6PDhizszN M3PqPHNCVkeHUh?=
TCCSUP NXjkTIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OwUGlEPTB;NT65N|I2QSEQvF2= NFfpeWZUSU6JRWK=
C2BBe1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[4[5NKSzVyPUWuPVM6PyEQvF2= NUjrT|E3W0GQR1XS
TE-15 NGHtTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTZwME[2NFUh|ryP MoDaV2FPT0WU
SCLC-21H NUCyVlNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rFemlEPTB;Nj6xNFg1OyEQvF2= M1rOUHNCVkeHUh?=
EoL-1-cell NYLvSYZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHBV4xKSzVyPU[uNVY2PjNizszN NInQeo1USU6JRWK=
NKM-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnVTWM2OD14LkG2O|Eh|ryP NWTKXZN2W0GQR1XS
NCI-H1304 NYrh[mFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XxVWlEPTB;Nj6yO|QzQCEQvF2= NFPmZ4pUSU6JRWK=
NB6 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H6ZmlEPTB;Nj6yPVYzOiEQvF2= MUnTRW5ITVJ?
NALM-6 NHX6S|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr1TWM2OD14LkOzNlMh|ryP MVHTRW5ITVJ?
NCI-H522 M3jvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\xTWM2OD14LkOzN|A3KM7:TR?= MnvoV2FPT0WU
MV-4-11 NVnPcIVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHkTWM2OD14LkO3NFc6KM7:TR?= MWnTRW5ITVJ?
LB2241-RCC NX33TWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;rbXZKSzVyPU[uN|g3PjdizszN MX;TRW5ITVJ?
NCI-H1417 M4Dne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\PTWM2OD14LkSwPFQ4KM7:TR?= NFfsb41USU6JRWK=
HT-1197 NXXkZXNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLETWM2OD14LkW3NVIzKM7:TR?= NYPkSZNnW0GQR1XS
P30-OHK MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTZwNkK3O{DPxE1? M3frTnNCVkeHUh?=
ALL-PO NXXFNopnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPOcGtKSzVyPU[uO|E6OTZizszN M{fRXHNCVkeHUh?=
OVCAR-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KwfmlEPTB;Nj63OVQxPSEQvF2= NH3vXpRUSU6JRWK=
HCC2157 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW1XWk1UUN3ME22Mlc4PDd3IN88US=> Ml3CV2FPT0WU
NCI-H838 NICxV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTZwOU[0PUDPxE1? MXjTRW5ITVJ?
NCI-H1299 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L4WmlEPTB;Nj65O|A6KM7:TR?= MX\TRW5ITVJ?
SW954 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DjeGlEPTB;Nz6yNFA3QCEQvF2= NUTHcIR3W0GQR1XS
NCI-H441 M3;Gbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzYRmE1UUN3ME23MlM1ODZ3IN88US=> NHPKdZpUSU6JRWK=
SK-MEL-2 M4X6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni5TWM2OD15LkS4N|c{KM7:TR?= NFP2RYtUSU6JRWK=
KARPAS-45 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTpTWM2OD15Lk[1PVI6KM7:TR?= MYTTRW5ITVJ?
CAL-54 NXzLOYQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTdwOEK5O|ch|ryP M3jzRnNCVkeHUh?=
KYSE-180 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITtSGJKSzVyPUeuPFg6PDFizszN NF3wXIpUSU6JRWK=
NCI-H187 NVfOZ|ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjvTWM2OD15Lkm1PVQ4KM7:TR?= M1LxNXNCVkeHUh?=
RT-112 M4XaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRThwMEm2O|ch|ryP NXPCWGVCW0GQR1XS
NCI-H1437 NIjXb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPpXFFXUUN3ME24MlA6Pzl3IN88US=> NFPhfI5USU6JRWK=
SNU-449 M{exT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjDfW1EUUN3ME24MlI5Ojd{IN88US=> M2TKNXNCVkeHUh?=
HCC1187 M1Haemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm4Xo1KSzVyPUiuNlk{QTFizszN NIHWTZRUSU6JRWK=
NCI-H2030 NIn3UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrZS|BKSzVyPUiuN|c4OTRizszN NVnvNGVEW0GQR1XS
HuO-3N1 M4\mNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvRTWM2OD16LkO3PFQ1KM7:TR?= MVzTRW5ITVJ?
COLO-792 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfOTWM2OD16LkSxOVI4KM7:TR?= Mn\1V2FPT0WU
MIA-PaCa-2 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;BTWM2OD16Lki1OVA5KM7:TR?= MWnTRW5ITVJ?
SK-N-FI NH;yOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLCTWM2OD17LkC0NlUh|ryP NYS0XoNVW0GQR1XS
MMAC-SF M1vNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G2dWlEPTB;OT6wPVc2OSEQvF2= MYDTRW5ITVJ?
NCI-H28 M{DwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfxR4U3UUN3ME25MlExPDZ7IN88US=> NH3FSJVUSU6JRWK=
ETK-1 M{\TU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf2PXZKSzVyPUmuNlk6PzRizszN M3TyS3NCVkeHUh?=
NCI-H1993 M4fUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfJfG5KSzVyPUmuOFQzPjFizszN M{TPdHNCVkeHUh?=
no-11 MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLF[nhKSzVyPUmuOFcyOiEQvF2= Ml;nV2FPT0WU
ChaGo-K-1 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SyZ2lEPTB;OT61NVU5OyEQvF2= MUPTRW5ITVJ?
NCCIT M{i3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G1Z2lEPTB;OT61N|E3QSEQvF2= M{jDcnNCVkeHUh?=
SAS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFyLkK0PEDPxE1? Ml3BV2FPT0WU
A673 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFyLkO3NFQh|ryP M4f5[3NCVkeHUh?=
NCI-H1522 M2HBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFyLkO3NFch|ryP NVTqZ5k3W0GQR1XS
NCI-H810 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXERodKSzVyPUGwMlM6ODdizszN NGfLTZZUSU6JRWK=
IST-MES1 M17k[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nuWGlEPTB;MUCuOFU3PCEQvF2= NVHFUWI6W0GQR1XS
GR-ST MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIThZnNKSzVyPUGwMlUxOjRizszN MlXTV2FPT0WU
SUP-T1 NG\T[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDkXJB[UUN3ME2xNE44OzF5IN88US=> NIjKN2RUSU6JRWK=
NB5 NGXMTnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnaTWM2OD1zMD65NFIzKM7:TR?= NXS5[os3W0GQR1XS
MZ1-PC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13hVWlEPTB;MUCuPVU4OSEQvF2= MYLTRW5ITVJ?
SK-CO-1 NVTuWFNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITwbpJKSzVyPUGwMlk6OzFizszN MULTRW5ITVJ?
Capan-2 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjrTWM2OD1zMT6zNVk5KM7:TR?= MlW1V2FPT0WU
697 MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC4WIlKSzVyPUGxMlY4PTdizszN NF\iWFlUSU6JRWK=
REH MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf2TWM2OD1zMT63OFUyKM7:TR?= NYrT[md3W0GQR1XS
GI-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnQTWM2OD1zMT64OlE2KM7:TR?= MXnTRW5ITVJ?
BB65-RCC MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjScXBmUUN3ME2xNk4xQTF4IN88US=> NVTQSHZsW0GQR1XS
NCI-H1651 NGXuU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nFOmlEPTB;MUKuNlQ4QCEQvF2= NV3icmc3W0GQR1XS
NCI-H1618 M3nyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF{LkO5O|Yh|ryP MlO1V2FPT0WU
NCI-H2081 NGDvUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK0TWM2OD1zMj62NVQyKM7:TR?= MXXTRW5ITVJ?
GCIY MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z5VmlEPTB;MUKuO|IyOyEQvF2= MWHTRW5ITVJ?
NY NHvCTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF|LkC2OFMh|ryP MYnTRW5ITVJ?
PANC-03-27 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3TdHNyUUN3ME2xN{4xQDB5IN88US=> NF7ndlVUSU6JRWK=
BHY MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7hbJNZUUN3ME2xN{4zOTJzIN88US=> NIDRPGRUSU6JRWK=
SK-OV-3 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\Xb2hyUUN3ME2xN{4{PzZ|IN88US=> NWHZfXRTW0GQR1XS
5637 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XXNGlEPTB;MUOuO|c2QSEQvF2= NVvT[GlIW0GQR1XS
LC-1F NYDUVFVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW1UJBSUUN3ME2xOE4xOzV4IN88US=> MXPTRW5ITVJ?
SNB75 Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfKNYpqUUN3ME2xOE4xOzh|IN88US=> MV\TRW5ITVJ?
CHP-212 MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTvVHhKSzVyPUG0MlA1PjRizszN NH7ae5hUSU6JRWK=
HT-1376 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nlU2lEPTB;MUSuNVEzPiEQvF2= MoXzV2FPT0WU
MONO-MAC-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjMW|VKSzVyPUG0MlE2ODJizszN NH7rPFNUSU6JRWK=
CA46 M1H2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP4fWdKSzVyPUG0MlE5OjdizszN MUfTRW5ITVJ?
SCC-15 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\JTWM2OD1zND61OVg{KM7:TR?= M4fMO3NCVkeHUh?=
ATN-1 NYW5[IJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;HTWM2OD1zND62OlI4KM7:TR?= MnXwV2FPT0WU
NCI-H2405 NXfPdot{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tpd2lEPTB;MUSuPFE2PyEQvF2= NGmw[VRUSU6JRWK=
NCI-H716 NEjGcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\MdYVLUUN3ME2xOE45PDl|IN88US=> NV3mdGkxW0GQR1XS
SW620 NFfyV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCxTWM2OD1zND65NFE1KM7:TR?= MXHTRW5ITVJ?
NCI-H226 NH3hN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPCXXNKSzVyPUG0MlkxQDVizszN MlHRV2FPT0WU
SW962 NWDtVnJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC1TWM2OD1zND65OFMzKM7:TR?= NXjoboM4W0GQR1XS
KYSE-150 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ibGlEPTB;MUSuPVU2KM7:TR?= M{fJfXNCVkeHUh?=
OCUB-M M37oRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyyZo9IUUN3ME2xOE46QDh|IN88US=> Mlr2V2FPT0WU
ES7 NGfOPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vOcmlEPTB;MUWuNFk5PCEQvF2= NEXOZ|lUSU6JRWK=
SW1463 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vRfGlEPTB;MUWuOFIzOyEQvF2= MWrTRW5ITVJ?
CAKI-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojWTWM2OD1zNT61N|Q3KM7:TR?= MmT6V2FPT0WU
MKN28 NVjIO5FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnPXG1KSzVyPUG1MlU1PzlizszN NVXuNJFvW0GQR1XS
SW13 M160Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjFTGMyUUN3ME2xOU43OThizszN NEHoSFBUSU6JRWK=
A3-KAW MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF3Lkm2PVch|ryP MYjTRW5ITVJ?
LU-65 NV61RpY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTZSmpFUUN3ME2xOU46PzZ6IN88US=> M3zXNnNCVkeHUh?=
Calu-1 M1\weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\4U3FKSzVyPUG2MlA{PjhizszN MofvV2FPT0WU
ST486 NYLnRnBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorxTWM2OD1zNj6wOFMyKM7:TR?= MVfTRW5ITVJ?
BB30-HNC NFTmWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDYfFNTUUN3ME2xOk4yOjR4IN88US=> NEjhUXFUSU6JRWK=
EGI-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLFNolKUUN3ME2xOk41PDZizszN NIDhSYFUSU6JRWK=
SH-4 NVjtd2FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrnTWM2OD1zNj60O|MyKM7:TR?= NUnSOJRJW0GQR1XS
MN-60 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPkTWM2OD1zNz6yNlk4KM7:TR?= MXnTRW5ITVJ?
MPP-89 NXrUSFJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfFO4tFUUN3ME2xO{4zPDV7IN88US=> M1zPVXNCVkeHUh?=
A2780 NFfLRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjPR5dRUUN3ME2xO{41OTN7IN88US=> NWPpfWhbW0GQR1XS
Daoy MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF5LkS2PVUh|ryP NIqwUVJUSU6JRWK=
NCI-H2126 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LmN2lEPTB;MUeuOFc4OSEQvF2= Ml;QV2FPT0WU
NCI-H1563 Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXmTWM2OD1zNz60PVE4KM7:TR?= NF60PWNUSU6JRWK=
8-MG-BA NGX0OYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXZTWM2OD1zNz62OlQ5KM7:TR?= NEXOTmhUSU6JRWK=
786-0 M2Tl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfMTWM2OD1zNz64N|U{KM7:TR?= NXf1UWl2W0GQR1XS
AM-38 Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m5V2lEPTB;MUeuPVMxPiEQvF2= Mn7MV2FPT0WU
COLO-824 NGe2eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;YNlFOUUN3ME2xPE41PDN4IN88US=> M2LifnNCVkeHUh?=
SK-MEL-30 NEi5XHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HMU2lEPTB;MUiuOVA5OiEQvF2= NIPEb|dUSU6JRWK=
CESS MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13FVGlEPTB;MUiuO|YxQSEQvF2= M33s[3NCVkeHUh?=
BL-70 NIPSNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH3T3pKSzVyPUG4MlgyPTZizszN MkfQV2FPT0WU
NCI-H2170 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[4SXRKSzVyPUG4MlkyPzlizszN M3vjUXNCVkeHUh?=
HT-3 NYjSRplFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnHTWM2OD1zOD65PFMh|ryP MYjTRW5ITVJ?
BOKU NEPZO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHlSWZKSzVyPUG5MlA{QDFizszN NH3hXohUSU6JRWK=
HPAF-II Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;GU3NKSzVyPUG5MlMxOTVizszN M{jrb3NCVkeHUh?=
KGN MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTCO4pKSzVyPUG5MlQ4PjVizszN NXjMb4t1W0GQR1XS
MC-CAR NVTYPYF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF7Lk[zNVMh|ryP M{HBfHNCVkeHUh?=
BHT-101 NIm0O2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL1TWM2OD1zOT63O|ch|ryP NEnYXWlUSU6JRWK=
SW1783 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLTN2VrUUN3ME2xPU44QDB4IN88US=> NWiybYN5W0GQR1XS
KP-N-YN MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u1RmlEPTB;MkCuNFI3OiEQvF2= MWrTRW5ITVJ?
LU-165 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj4SFV6UUN3ME2yNE42PTdzIN88US=> MXLTRW5ITVJ?
GOTO NXrjXXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXOc2MxUUN3ME2yNE43PDVzIN88US=> M{[5Z3NCVkeHUh?=
EFM-19 NYHzVXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrlTWM2OD1{MT6wO|E3KM7:TR?= M163ZXNCVkeHUh?=
CTV-1 NFfMWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fxWmlEPTB;MkGuNVA2PCEQvF2= MnixV2FPT0WU
HEL MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj2dGgzUUN3ME2yNU41OjF4IN88US=> NWXDNFNsW0GQR1XS
SNU-C2B MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37mW2lEPTB;MkGuOFI3KM7:TR?= MYjTRW5ITVJ?
ECC4 NXXY[ZhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq1TWM2OD1{MT63NFch|ryP M2POe3NCVkeHUh?=
NEC8 NVGxXGZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHBSGdKSzVyPUKxMlg{PjhizszN MVHTRW5ITVJ?
KMOE-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3IVHB6UUN3ME2yNU45QTJzIN88US=> MVTTRW5ITVJ?
NCI-H524 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LvdGlEPTB;MkKuNFgxQCEQvF2= NHfxO45USU6JRWK=
WSU-NHL NUTOfW5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TD[mlEPTB;MkKuNVU4PyEQvF2= MoH1V2FPT0WU
SF126 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K1XGlEPTB;MkKuNlQ3QSEQvF2= MkDOV2FPT0WU
HOP-92 M4DVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nqVmlEPTB;MkKuN|E3PyEQvF2= NWLIbZpWW0GQR1XS
CTB-1 M4i3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ{LkS2O|ch|ryP NEHCeZBUSU6JRWK=
KYSE-270 NIfFdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPNVVJKSzVyPUKyMlk{PTdizszN Mnr1V2FPT0WU
SK-MEL-24 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPUSGtWUUN3ME2yN{4yQDdizszN M3LHUnNCVkeHUh?=
Calu-3 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPjc2xKSzVyPUKzMlIyOjhizszN M3HwVHNCVkeHUh?=
GAMG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLWTWM2OD1{Mz6yN|Y4KM7:TR?= MX\TRW5ITVJ?
SW1573 NIraRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;IWXhYUUN3ME2yN{44PDF3IN88US=> MmT4V2FPT0WU
MHH-NB-11 M4fidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\EU4dKSzVyPUK0MlAyQTRizszN NIT5N4RUSU6JRWK=
TK10 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH4TWM2OD1{ND61NFE{KM7:TR?= M4rDe3NCVkeHUh?=
LB373-MEL-D MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jXXGlEPTB;MkSuOlA3PCEQvF2= MWHTRW5ITVJ?
KALS-1 NWTpVZJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfuO4hKSzVyPUK0Mlc{OjdizszN NXPsOnVqW0GQR1XS
HUTU-80 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ3LkiwN|Ih|ryP NFTCRpJUSU6JRWK=
HuP-T3 NVLySpFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnOTWM2OD1{Nj6xOlc1KM7:TR?= M2XjZXNCVkeHUh?=
OE19 M1y3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ4LkKxOVMh|ryP M4KzTnNCVkeHUh?=
J82 NYi2dFdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7kTWM2OD1{Nj6yOFcyKM7:TR?= M{DzTHNCVkeHUh?=
DU-4475 NIKyVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJ4LkO4NVkh|ryP NHXRRoRUSU6JRWK=
DMS-53 NXO4Z3c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6yNJk1UUN3ME2yOk42OTN6IN88US=> NHTjN21USU6JRWK=
COLO-741 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ4LkizOFQh|ryP NHzZXVlUSU6JRWK=
SW48 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7QRZA4UUN3ME2yOk45QDJizszN NInEWlVUSU6JRWK=
IGR-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;tV25KSzVyPUK2Mlk{OzRizszN M2LVbXNCVkeHUh?=
639-V MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnviTWM2OD1{Nz6wNlQ2KM7:TR?= M{\ITnNCVkeHUh?=
LK-2 M2G5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS5TWM2OD1{Nz60NVQyKM7:TR?= M17WdHNCVkeHUh?=
NCI-H2347 NGrMdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTiNodDUUN3ME2yO{46Pjl7IN88US=> MofaV2FPT0WU
NCI-H2228 M3LIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ6LkC5NFUh|ryP NE\ESIhUSU6JRWK=
LS-123 M2jhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzTTWM2OD1{OD6xNlYzKM7:TR?= NWDa[WVqW0GQR1XS
U031 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDMOVh{UUN3ME2yPE4zPTJizszN NIGyVYxUSU6JRWK=
NCI-H1792 NHzPd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ6LkS3NlEh|ryP MUnTRW5ITVJ?
NCI-H2087 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj4WFZ6UUN3ME2yPE44PTV{IN88US=> NW\3NWxXW0GQR1XS
NCI-H2342 M{DG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW5TopMUUN3ME2yPU42OjB6IN88US=> MYfTRW5ITVJ?
SW626 MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTTPVdlUUN3ME2yPU44PTZizszN NFnIWJBUSU6JRWK=
LB2518-MEL NEixNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOwNW9KSzVyPUK5MlgyPSEQvF2= NHjRNXVUSU6JRWK=
RXF393 NHT3WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC2XHlYUUN3ME2zNE4xQTV{IN88US=> M1n2T3NCVkeHUh?=
LC4-1 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn5O3F3UUN3ME2zNE4{ODl{IN88US=> NF\3OpJUSU6JRWK=
NCI-H1694 NEO3WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLNbnZKSzVyPUOwMlY3OjRizszN NFHuVZBUSU6JRWK=
K5 MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTMbFJUUUN3ME2zNE46PzB{IN88US=> M1rRUXNCVkeHUh?=
HDLM-2 NEXQT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT2OJVYUUN3ME2zNE46PzJ3IN88US=> NEPIUnBUSU6JRWK=
BCPAP MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLVdXlKSzVyPUOxMlg{PzlizszN MXTTRW5ITVJ?
BC-3 M2nMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\VcWlEPTB;M{KuNVQxOyEQvF2= MmGwV2FPT0WU
LB996-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr1N5RCUUN3ME2zNk4zOzV6IN88US=> M3j2OnNCVkeHUh?=
NCI-H2009 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN{LkS5PFEh|ryP M3nM[nNCVkeHUh?=
HTC-C3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN|Lke1NVkh|ryP NEjZeotUSU6JRWK=
LAMA-84 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTTTWM2OD1|ND60OFA4KM7:TR?= NWPMbI85W0GQR1XS
CCRF-CEM MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjjTJpsUUN3ME2zOE42PzF3IN88US=> NFfQdYhUSU6JRWK=
AN3-CA M{[5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLk[otKSzVyPUO1MlA2PjhizszN MYDTRW5ITVJ?
NCI-H1734 NX3qe3FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGwTWM2OD1|NT6yOVYyKM7:TR?= M3f6fXNCVkeHUh?=
Ca-Ski M3j6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;BbVdUUUN3ME2zOU41OTBzIN88US=> M4TZZXNCVkeHUh?=
U-266 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTN3Lk[xNVQh|ryP NVrOVWprW0GQR1XS
SBC-5 M4LrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TadWlEPTB;M{WuO|c5OSEQvF2= M3jscXNCVkeHUh?=
GT3TKB MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTN5LkGxOUDPxE1? MmfCV2FPT0WU
MDA-MB-175-VII NILhTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHJeFJKSzVyPUO3MlIzPDhizszN M4fId3NCVkeHUh?=
PFSK-1 Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLzTWM2OD1|Nz6yOFM2KM7:TR?= MVjTRW5ITVJ?
IMR-5 M13qZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TRRWlEPTB;M{euNlQ5PyEQvF2= MV;TRW5ITVJ?
Daudi MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHsU4ZEUUN3ME2zO{4{PTl5IN88US=> NE\mcopUSU6JRWK=
A498 NXq2cVk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTN5LkeyNVgh|ryP NIfTbFFUSU6JRWK=
SCC-4 M{nHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTN5Lke4OFMh|ryP NEHheFlUSU6JRWK=
COLO-680N MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoflTWM2OD1|OD6yPFg2KM7:TR?= M2LC[HNCVkeHUh?=
SK-MES-1 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPxVZdKSzVyPUO4MlMzOTVizszN MVvTRW5ITVJ?
SR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPKc|NoUUN3ME2zPE42PDl3IN88US=> NF65NmlUSU6JRWK=
LNCaP-Clone-FGC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofJTWM2OD1|OD61OlM4KM7:TR?= M3P0UXNCVkeHUh?=
SK-HEP-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nodGlEPTB;M{iuO|gzOiEQvF2= NUXib3V2W0GQR1XS
BPH-1 M{jKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;JUWlEPTB;M{iuPFMzQSEQvF2= NHfjO|hUSU6JRWK=
NCI-H1755 NIrpNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[4fYlKSzVyPUO5MlU5OTdizszN Mle1V2FPT0WU
LXF-289 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN7LkiwPFQh|ryP M1Hod3NCVkeHUh?=
SW1088 M1\IOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHmTWM2OD12MD6yNVA4KM7:TR?= M37uT3NCVkeHUh?=
MOLT-4 NFTob|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDrcJI{UUN3ME20NE4zQTBzIN88US=> MVfTRW5ITVJ?
AsPC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn6TWM2OD12MD60OVg{KM7:TR?= Mn34V2FPT0WU
HOP-62 M3PtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GwUmlEPTB;NECuOlU3QCEQvF2= MlK5V2FPT0WU
A172 M{HrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13BTmlEPTB;NECuPFUyOSEQvF2= NUWzdXlpW0GQR1XS
SN12C NUnrZVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXriSWlpUUN3ME20NE46Ozh3IN88US=> Moj4V2FPT0WU
MDA-MB-231 NGfNXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7aXotZUUN3ME20NE46QDl6IN88US=> MXvTRW5ITVJ?
RPMI-2650 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTRzLkG1PVMh|ryP NH6wUG5USU6JRWK=
KYSE-140 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\DRWlEPTB;NEGuPFEzOyEQvF2= MkfTV2FPT0WU
KINGS-1 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofFTWM2OD12Mj60Olk4KM7:TR?= MVjTRW5ITVJ?
HSC-3 M2XNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rrW2lEPTB;NEKuOlY3OSEQvF2= MVHTRW5ITVJ?
PC-14 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLoWoVKSzVyPUSzMlE5QDJizszN NVHSZ|IxW0GQR1XS
COR-L105 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TVT2lEPTB;NEOuOlUxOiEQvF2= NW\IV29rW0GQR1XS
BE-13 M3GxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHUUGVKSzVyPUS0MlI{PzFizszN NVrFSnJxW0GQR1XS
NCI-H661 MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHJcoZKSzVyPUS0MlI6PThizszN MUjTRW5ITVJ?
IST-MEL1 NWnQZ2ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TIdGlEPTB;NESuN|U6QSEQvF2= NGLGeJNUSU6JRWK=
HCC1806 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTR2LkW4O|Mh|ryP MYLTRW5ITVJ?
COLO-800 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe4bVZKSzVyPUS0Mlg1PTNizszN MXrTRW5ITVJ?
IST-SL2 NF7rbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTR3LkGyOFch|ryP M{DrRXNCVkeHUh?=
8305C MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTyTWM2OD12NT6zNFkh|ryP NXHVbpZkW0GQR1XS
UACC-62 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M123UGlEPTB;NE[uNlg4PSEQvF2= MYPTRW5ITVJ?
COR-L23 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\xeJdKSzVyPUS3MlE6QSEQvF2= MnzhV2FPT0WU
EFE-184 NYjybWJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi4OFhRUUN3ME20O{4{QDhizszN NXOw[3hXW0GQR1XS
DMS-114 NF\4SWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\XUmlEPTB;NEeuOFE1QSEQvF2= M{X3[HNCVkeHUh?=
KYSE-520 NU\XeGp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrPOnZKSzVyPUS4MlU{OTVizszN M2CwWnNCVkeHUh?=
SNG-M Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PZTGlEPTB;NEmuOFM1KM7:TR?= M3nkNHNCVkeHUh?=
A2058 NGXaZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTR7LkS4PFUh|ryP NEnLcWRUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型,抑制肿瘤生长,按 75 mg / kg剂量处理,导致100% TGI和 55% 衰退,按25 mg/kg剂量处理,导致 60% TGI,没有衰退。OSI-906处理犬,大鼠和小鼠,诱导不同的消除半衰期,消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠,每天一次,Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天,提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型,在4 和24小时间最大程度抑制IGF-IR磷酸化(80%),血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠,处理2,4,24小时,抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型,抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中,使用聚 (Glu:Tyr)作为底物,结合到96孔实验板表面,使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物,通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中,人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白,且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验,除非另有说明,取三次测量的最小值。
细胞实验:[1]
+ 展开
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖,细胞接种在含FCS 10%的合适培养基上,在不同浓度OSI-906存在时,温育3天。通过细胞内ATP含量的荧光量化,使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分,通过在不同浓度 OSI-906存在时的细胞密度除以对照组(只用DMSO处理)细胞密度。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Formulation: 25 mM 酒石酸
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理,每天一次,持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O

CAS号 867160-71-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID